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Table　1　Patient characteristics
mean ± SE range
Duration of asthma (years) 8.62 ± 1.31 1-22
Age (years) 57.0 ± 3.75 29-80
Number of patients (Male/Female) 8/13
Smoking history (Never/Ex-smoking) 15/6
Concomitant drugs other than SFC 
(None/Use)
7/14
Fourteen were additionally on concomitant drugs: nine were on
leukotriene antagonist (LTRA), one was on theophylline (Theo),
and one each was on LTRA plus Theo and LTRA plus  oral anti-al-
lergic compound respectively.
Dear Editor
Efficacy of Budesonide in Combination
with Formoterol in Patients with
Inadequately Controlled Asthma on
Fluticasone in Combination
with Salmeterol
Global Initiative for Asthma ( GINA ) guidelines
(GINA 2010) advocate the use of inhaled corticoster-
oids combined with a long-acting inhaled β2-agonist
in a single inhaler (ICSLABA) in Treatment Steps 3
through 5 for bronchial asthma.1 Fluticasone in com-
bination with salmeterol (FPSM) is effective in pa-
tients with moderate to severe asthma,2 but some pa-
tients do not resolve the persistent symptoms and re-
quire step up treatments. Therefore, the efficacy of
budesonide in combination with formoterol (BUD
FM) was assessed in patients with inadequately con-
trolled asthma on FPSM.
Methods
224 patients with asthma received FPSM 25050 μg
bid more than 3 months between May and December
2010 in Respiratory Center of Takatsuki Red Cross
Hospital, Osaka, Japan. 29 patients were judged as
“not controlled” from the following questionnaire de-
fined by GINA 2010; daytime and nocturnal symp-
toms, limitation of activities, and the frequency of
need for reliever. After inhalation guidance instruc-
tion, peak expiratory flow (PEF) measured with a
Mini-WrightⓇ peak flow meter, routine usage of FP
SM, and need for short-acting inhaled β2-agonists
(SABA) were recorded in the asthma diary twice
daily. PEF measurements were repeated three times
every morning and evening before FPSM was taken
and the best of three attempts was recorded on each
occasion. As 26 of the patients did not improve symp-
toms after 1 month of inhalation guidance instruction
(Visit 1), they chose between increase dose of FP or
other ICS andor add-on of other controllers, or
switch to BUDFM 3209 μg bid. All 26 patients se-
lected to switch from FPSM to BUDFM and contin-
ued to note their diary. The lowest morning PEF over
a week, expressed as a percent of the recent best
(Min%Max), which has been suggested as correlating
with airway hyperresponsiveness (AHR)3 was calcu-
lated every 4 weeks. The lowest morning PEF over a
week defined the lowest daily mPEF in the previous
week before each visit. The recent best was defined
as the highest PEF over all of asthma diary. All data
from the diary at Visit 1 were compared with switch-
ing therapy after 4, 8 and 12 weeks (Visits 2-4) re-
spectively. At Visits 1 and 4, the Asthma Control
Questionnaire (ACQ-5) which consists of five ques-
tions; night-time waking, symptoms on waking, activ-
ity limitation, shortness of breath and wheezing, was
also completed.4
Results
A summary of the demographic and baseline charac-
teristics of the study subjects and asthma daily data
are shown in Table 1 and Figure 1 respectively. Since
4 of patients required step up treatments and the re-
maining 21 patients were analyzed. At Visit 1, all sub-
jects were classified according to GINA 2010 as mod-
erate persistent asthma and not well controlled (18
subjects were classified as partly controlled and 3 as
uncontrolled). None of the study subjects were cur-
rent smokers, but six were ex-smokers with a median
smoking history of 5.78 ± 2.31 pack-years. ACQ-5
scores significantly decreased from 1.3 at Visit 1 to
1.0 at Visit 4 (Fig. 1A). PEF showed significant im-
provements at the all Visits in the morning and eve-
ning from Visit 1 (Fig. 1B). Although no significant
differences were observed in any of the data with
need for SABA in the evening, morning requirement
of SABA on Visits 3 and 4 were improved from those
on Visit 1 (Fig. 1C). Min%Max obtained through Vis-
its 2 to 4 were also significantly increased from Visit 1
(Fig. 1D). Although adherence to therapy and pulmo-
nary spirometry were similar with no significant dif-
ference throughout the study periods, a 10% decline
was shown in Visit 4 relative to Visit 1 ( data not
shown).
Discussion
This study confirmed that when inadequately uncon-
trolled asthmatic patients by FPFM were switched
to BUDFM, they exhibited significant improve-
ments in ACQ-5, PEF, Min%Max, and requirement of
morning SABA, suggesting good asthma control.
Many articles have reported the efficacy of BUDFM,
particularly the improvement in lung function and
asthma control in comparison with other ICS and
ICSLABA.4-10 Although, we did not confirm the as-
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Fig.　1　Change from baseline in the average of Asthma Control Questionnaire (A), PEF (B). The frequency of 
need for SABA (C) and Min%Max (D).
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sessment of airway inflammation by methods such as
methacholine inhalation challenge, our result sug-
gests that AHR improvement might be responsible
for their asthma control because GINA 2010 notes
that Min%Max correlates with AHR. On the other
hand, we could not provide the improvement in spi-
rometry. PEF were measured everyday on time and
calculated the average, meanwhile, spirometry meas-
urement represented the state at the examination and
ranged in different time among patients. This is the
possible reason for discrepancy between PEF and spi-
rometry findings. There are several limitations to this
study. First, it is possible that the observed Min%Max
improvement might have been due to the influence of
seasonal bias and differences between SM and FM.
In fact, no studies have shown that FM 18 μg and SM
100 μg are the same titer. Second, we could not as-
sess the efficacy of FPSM in patients who were not
well controlled on BUDFM. When patients whose
asthma is inadequately controlled by BUDFM are
switched to FPFM, they might experience similar
findings as observed in our result. Third, we should
have also evaluated the demographic data between
patients who were well controlled on FPSM and
those who were not. As a result, we could not find the
characteristics of patients with no effect of FPSM
and answer the question of which subgroup of pa-
tients should be recommended BUDFM. Finally,
switching to the other ICSLABA which is situated at
the same treatment dosage might not be effective ba-
sically because four patients required the step up.
However, in clinical practice, it has been often per-
formed an exchange from one ICS or ICSLABA to
another ICS or ICSLABA at the same treatment rec-
ommendation dose.
In conclusion, though our result is not applicable
all of patients with inadequately controlled asthma on
FPSM, the switching from FPSM 500100 μg daily
to BUDFM 64018 μg daily is effective in subset of
patients. Additional studies to evaluate the clinical dif-
ference between validity and invalidity case for each
BUDFM and FPSM are needed.
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